On the other hand, CBN, CBDA, CBCA, and CBC may potentially act as ER inverse agonists, which may be beneficial for ER+ breast cancer cases since, by presenting opposite actions to ER agonists, they prevent the tumorigenic effects of ERα. This evidence concerns the gene ESR1 and breast carcinoma.